After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...
AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback